BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
28. Mai 2019 16:10 ET
|
BioDelivery Sciences International, Inc.
New Agreement is Cash Flow Accretive, Lowers Cost of Capital and Extends Debt Maturity Reduces Annual Interest Costs by Approximately $1.5 million Increases Flexibility to Continue Growth Trajectory...
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
06. Mai 2019 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acquisition and Commercial Integration Successfully CompletedCompany Raises Full-Year BELBUCA Net...
BioDelivery Sciences to Report First Quarter 2019 Financial Results
25. April 2019 16:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock
11. April 2019 09:29 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 11, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced the pricing of an underwritten public offering by...
BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock
10. April 2019 16:07 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 10, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced that it is commencing an underwritten public...
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
10. April 2019 16:06 ET
|
BioDelivery Sciences International, Inc.
Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel treatment option for OIC ...
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
21. Februar 2019 07:45 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
04. Februar 2019 08:03 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
15. Januar 2019 07:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Jan. 15, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
08. November 2018 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...